Genentech posts Phase III win for Enspryng in MOGAD
Bottom line
Genentech said April 21 that its Phase III METEOROID trial met the primary endpoint for Enspryng (satralizumab) in myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, a rare neuroinflammatory disorder with no approved treatments. In adults and adolescents, satralizumab reduced the risk of a new relapse by 68% versus placebo, with 87% of treated patients relapse-free at 48 weeks compared with 67% on placebo. The company also reported statistically significant reductions in annualized relapse rate, MRI lesion activity, and rescue therapy use, and said the data will be submitted to regulators globally. (gene.com)
Why it matters: While this is a human neurology story rather than a veterinary one, it’s still relevant for veterinary professionals tracking translational immunology, monoclonal antibody development, and rare-disease regulatory strategy. Satralizumab targets the IL-6 receptor, is already approved in about 90 countries for AQP4-IgG seropositive NMOSD, and is given by subcutaneous injection with at-home self-administration after training. The MOG Project called the result “historic,” underscoring how closely patient groups are watching the possibility of a first approved therapy in MOGAD. (gene.com)
What to watch: Watch for regulatory filings in 2026 and for fuller peer-reviewed or congress-level data that clarify durability, subgroup performance, and how quickly satralizumab could become the first approved treatment for MOGAD. (gene.com)
Genentech has reported positive Phase III data for Enspryng (satralizumab) in MOGAD, saying the METEOROID study met its primary endpoint and may position the drug as the first approved treatment for the disease. In the late-breaking presentation at the 2026 American Academy of Neurology annual meeting in Chicago, the company said satralizumab reduced the risk of a new relapse by 68% compared with placebo in adults and adolescents with MOGAD. (gene.com)
That matters because MOGAD remains a rare autoimmune disease of the central nervous system with no approved therapies, despite the risk of recurrent attacks affecting the optic nerves, spinal cord, and brain. Genentech said the disorder can lead to cumulative neurological damage, vision loss, and disability when relapses aren’t controlled. The company’s update also fits a broader development arc for satralizumab, which was first approved in 2020 in the U.S. for AQP4-IgG seropositive neuromyelitis optica spectrum disorder, another neuroimmune disease in which IL-6 signaling is implicated. (gene.com)
The key efficacy details were stronger than a simple top-line readout. According to Genentech and Roche investor materials, 87% of patients receiving satralizumab were relapse-free at 48 weeks versus 67% on placebo, with onset of response seen as early as week 8. The annualized relapse rate fell by 66%, MRI-active lesions across the optic nerves, brain, and spinal cord fell by 79%, and the proportion of patients needing rescue therapy fell by 73%. Roche’s materials also reported a hazard ratio of 0.32, with adjudicated relapses in 13.2% of satralizumab-treated patients versus 37.5% on placebo. (gene.com)
The trial design adds useful context. METEOROID was a randomized, double-blind, placebo-controlled, multicenter Phase III study in patients aged 12 years and older. Participants were randomized 1:1 to satralizumab or placebo, with weight-based dosing given subcutaneously at weeks 0, 2, and 4, then every four weeks. Patients could remain on background immunosuppressive therapy, and those who relapsed or completed the blinded phase could enter an open-label extension. Company pipeline materials from Chugai had already pointed to a projected global submission in 2026, which now looks more actionable after these results. (gene.com)
On safety, Genentech said no new safety signals emerged and that the profile was consistent with prior clinical and post-approval experience in NMOSD. The most commonly reported adverse events occurring more often with satralizumab than placebo included injection-related reactions, influenza, arthralgia, back pain, sinusitis, and diarrhea. There was one fatality that the company said was not related to treatment, and none of the serious adverse events were considered treatment-related. (gene.com)
Outside the company, the reaction was notably positive. The MOG Project, a nonprofit focused on the disease, called the readout an “historic day” for children and adults living with MOGAD and highlighted the possibility that satralizumab could reduce not only relapses, but also dependence on rescue treatments such as steroids, plasma exchange, and intravenous immunoglobulins. That kind of response matters because rare-disease launches increasingly depend on alignment among sponsors, specialists, advocacy groups, and regulators, not just headline efficacy. (mogproject.org)
Why it matters: For veterinary professionals, this is less about immediate clinical application and more about the signals it sends across comparative medicine and biologics development. IL-6 remains an important inflammatory pathway across species, and satralizumab’s progress shows how targeted immunology programs can move from mechanistic rationale to pivotal data in small, heterogeneous rare-disease populations. It’s also a reminder that patient-friendly administration, in this case subcutaneous self-injection, is becoming part of the value story alongside efficacy and safety, a theme that increasingly carries over into animal health innovation as well. (gene.com)
What to watch: The next milestones are regulatory submissions, likely beginning in 2026, plus more detailed dataset disclosures that could shape uptake, including subgroup analyses, durability in the open-label extension, and any regional filing or review timelines. If regulators move quickly, satralizumab could become the first approved therapy specifically labeled for MOGAD. (gene.com)